Results 11 to 20 of about 13,334 (226)

Spirometric Indices after Bronchodilator Test in Obstructive Lung Disease [PDF]

Acta Medica Iranica, 2010
"nBronchial responsiveness to bronchodilator medications is usually tested to establish reversibility of airflow obstruction. Among the various tests to establish bronchodilator response, FEV1, FEF25-75% or FEF50%, and FVC are the most widely used ...
Amir Houshang Mehrparvar, Seyed Jalil Mirmohammadi, Mohammad Mehdi Sohrabi   +2 more
doaj   +2 more sources

Paediatrics: how to manage acute asthma exacerbations

Drugs in Context, 2021
Background: Asthma is the most common chronic disease of childhood and a major source of childhood health burden worldwide. These burdens are particularly marked when children experience characteristic ‘symptom flare-ups’ or acute asthma exacerbations ...
James S Leung
doaj   +1 more source

Long-acting β2-adrenergic receptor agonist in pediatric asthma

Allergology International, 2004
Long-acting β2-adrenergic receptor agonists (LABA), a class of agents for the long-term management of childhood bronchial asthma, are recommended for use in combination with steroid inhalation for the treatment of the morning dip in severe childhood ...
Shigemi Yoshihara, Yumi Yamada, Toshio Abe, Osamu Arisaka   +3 more
doaj   +1 more source

Evaluation of bronchodilators and mucolytic agents.

Journal of postgraduate medicine, 1979
S R Kamat
openaire   +3 more sources

Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness

Allergy, Asthma & Clinical Immunology, 2007
Anticholinergics, or specific antimuscarinic agents, by inhibition of muscarinic receptors cause bronchodilatation, which might correlate with activation of these receptors by the muscarinic agonist methacholine.
Petanjek Bojana B, Grle Sanja P, Pelicarić Dubravka, Vranković Dubravka   +3 more
doaj   +1 more source

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety

Therapeutic Advances in Respiratory Disease, 2015
The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo, Marcello Montagni, Gian Galeazzo Riario-Sforza, Marco Baroni, Cristoforo Incorvaia   +4 more
doaj   +1 more source

Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial

BMC Pulmonary Medicine, 2018
Background In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88–92 ...
George Bardsley, Janine Pilcher, Steven McKinstry, Philippa Shirtcliffe, James Berry, James Fingleton, Mark Weatherall, Richard Beasley   +7 more
doaj   +1 more source

A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation

Lung India, 2016
Context: The combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) is widely used in the treatment of moderate-to-severe asthma uncontrolled by ICS alone. Aims: To evaluate the efficacy and safety of a new ICS-LABA combination
Sundeep S Salvi, Abhijit J Vaidya, Rahul R Kodgule, Jaideep A Gogtay   +3 more
doaj   +1 more source

An update on the use of indacaterol in patients with COPD

Therapeutic Advances in Respiratory Disease, 2011
Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease.
Nadia S. Brienza, Óscar Amor-Carro, David Ramos-Barbón   +2 more
doaj   +1 more source

Investigation of the assortment of medicines for the treatment of chronic obstructive pulmonary disease in the pharmaceutical market of Ukraine

Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2020
The aim of the work – to analyze the assortment of medicines for the treatment of chronic obstructive pulmonary disease (COPD) (bronchodilator therapy (BT). in the modern pharmaceutical market of Ukraine. Materials and Methods.
L. I. Budniak , Ye. Yu. Dynia
doaj   +1 more source